secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRESCENT BIOPHARMA, INC. (CBIO)
CIK:        0001253689
Form:       8-K
Filed at:   2024-05-06T23:59:59+00:00
Accession:  0001558370-24-006793
Event type: other_material
Sentiment:  negative
Materiality: 0.95
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GlycoMimetics' pivotal Phase 3 trial of uproleselan in R/R AML fails to meet primary endpoint of overall survival
--------------------------------------------------------------------------------

- Phase 3 study (388 patients) of uproleselan + chemo did not achieve statistically significant improvement in overall survival vs chemo alone.
- Median overall survival 13 months (uproleselan) vs 12.3 months (placebo).
- NCI Phase 2/3 study in newly diagnosed AML remains ongoing; company will submit data to medical meeting.
- Cash and cash equivalents $31.3M as of March 31, 2024, down from $41.8M at Dec 31, 2023.
- Q1 2024 R&D expenses $6.0M, G&A $5.1M; shares outstanding 64.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1253689/000155837024006793/0001558370-24-006793-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1253689/000155837024006793/glyc-20240506x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-006793

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer